RG 7667

Drug Profile

RG 7667

Alternative Names: MCMV-3068A; MCMV-5322A; RG-7667; RO-6855848; RO-6855849

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Genentech
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 16 Oct 2014 Discontinued - Phase-II for Cytomegalovirus infections (Prevention) in USA, UK, Belgium, France, Germany, Norway, Spain, Sweden (IV)
  • 15 Sep 2014 Genentech completes a phase II trial in Cytomegalovirus infections in USA, United Kingdom, Belgium, Germany, France, Norway, Spain and Sweden (EudraCT2012-002245-37)
  • 01 Feb 2013 Genentech completes a phase I trial in Healthy volunteers in USA (NCT01496755)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top